



Invitation

Stockholm February 1, 2021

Invitation to presentation of Bactiguard's year-end report for 2020 on February 4, 2021

Bactiguard Holding AB (publ) publishes the year-end report for 2020 on Thursday, February 4, 2021 at 8:00 CET.

In connection with this, an audiocast for investors, analysts and media will be held at 10:30 CET on February 4. CEO Cecilia Edström and CFO Gabriella Björknert Caracciolo will present the year-end report and answer questions. The report and a presentation for the audiocast will be available at Bactiguard's website www.bactiguard.com

To participate in the audiocast, please use this link:

<https://tv.streamfabriken.com/bactiguard-q4-2020>

To participate only by conference call, please dial:

SE: +46850558353, UK: +443333009271, US: +18338230589

Questions can be asked either in writing via the audiocast or orally if you attend the conference call.

For further information, please contact:

Gabriella Björknert Caracciolo, CFO and deputy CEO, mobile: +46 72 141 62 49

About Bactiguard

Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.

The Bactiguard technology is based on a thin noble metal alloy coating that prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Urinary catheters with Bactiguard's coating are market leaders in the USA and Japan through our licensing partner BD.

Bactiguard's product portfolio also includes Hydrocyn® aqua, a non-alcoholic product line for wound care and disinfection. Hydrocyn effectively kills viruses, bacteria and fungi while being biocompatible, pH neutral and tissue friendly. The active ingredient hypochlorous acid is the same substance as the body's immune cells use in their defence against infectious organisms.

Bactiguard is in a strong expansion phase in the markets in Europe, China, India and the Middle East through our own product portfolio and by establishing licensing deals in new therapy areas.



Bactiguard has about 180 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia. Bactiguard is listed on Nasdaq Stockholm.

Read more about Bactiguard www.bactiguard.com